Physician profile
Sumit Kumar
NPI 1598743098
$166,486.11
in general payments reported to CMS, 2019-2025
42 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $5,193 · 2021: $29K · 2022: $27K · 2023: $4,736 · 2024: $61K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $8,980 · Food and Beverage: $6,351 · Consulting Fee: $5,525 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,145.00 |
| Travel and Lodging | $8,980.30 |
| Food and Beverage | $6,350.66 |
| Consulting Fee | $5,525.00 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $45,206.30 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33,371.17 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $32,278.63 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $23,514.96 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Travere Therapeutics, INC. | $16,917.44 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $7,650.90 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,246.82 | 2019-2025 | Farxiga, Lokelma |
| Intuitive Surgical, INC. | $1,190.22 | 2023 | Da Vinci Surgical System |
| Amgen INC. | $516.90 | 2019-2025 | Krystexxa, Tavneos |
| Janssen Pharmaceuticals, INC | $424.25 | 2019-2020 | |
| Cormedix INC. | $364.82 | 2024 | Defencath |
| Calliditas Therapeutics US INC. | $364.52 | 2022-2024 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $359.59 | 2020-2024 | Terlivaz |
| Boston Scientific Corporation | $332.53 | 2025 | 2cm Peripheral Cutting Balloon |
| Otsuka America Pharmaceutical, INC. | $325.53 | 2019-2025 | Voyxact, Jynarque |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $316.60 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Ardelyx, INC. | $240.68 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $210.51 | 2021-2023 | |
| Opko Pharmaceuticals, LLC | $174.67 | 2019-2025 | Rayaldee |
| Teleflex LLC | $144.93 | 2024 | Guideliner |
| Vifor Pharma, INC. | $139.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $124.29 | 2020-2022 | |
| Akebia Therapeutics INC | $120.69 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $114.99 | 2019 | |
| La Jolla Pharmaceutical Company | $107.85 | 2019 | |
| Outset Medical INC | $100.82 | 2024 | |
| Novo Nordisk INC | $90.56 | 2021-2025 | Ozempic |
| Alnylam Pharmaceuticals INC. | $78.08 | 2021-2022 | |
| Philips North America LLC | $71.09 | 2022 | |
| Renalytix Ai, INC. | $68.77 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Genzyme Corporation | $64.92 | 2019-2024 | |
| Vertex Pharmaceuticals Incorporated | $55.92 | 2022 | |
| Genentech, INC. | $51.71 | 2022 | |
| Scpharmaceuticals INC. | $41.90 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $38.16 | 2019 | |
| Shire North American Group INC | $21.47 | 2019 | |
| Medtronic, INC. | $18.44 | 2024 | Ellipsys Vascular Access System |
| Pfizer INC. | $13.63 | 2019 | |
| Ethicon US, LLC | $11.20 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.